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 Introduction 
 During the first year of life, the body iron content in-
creases markedly. In healthy term infants, iron stores at 
birth comprise most of the iron requirements for the first 
4–6 months. From the 4th month, the requirement for 
dietary iron increases to an estimated 0.78 mg/day due to 
the stepwise depletion of endogenous stores and rapid 
growth with an expansion of blood volume and increased 
tissue and storage iron  [1] . Rapid growth with high iron 
needs makes infants and young children a particular risk 
group for iron deficiency anemia (IDA), especially those 
aged 6–24 months  [2] . Adolescents are another risk group 
for the development of IDA because of rapid growth and 
increased iron demands during puberty. This is partic-
ularly true for adolescent girls due to menstrual losses 
 [3,  4] . In addition to inadequate intake, factors which 
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 Abstract 
 A systematic review was conducted to summarize the evi-
dence currently available from randomized controlled trials 
(RCTs) concerning the effect of iron intake of infants, children 
and adolescents on measures of cognitive development and 
function. The Cochrane Library, MEDLINE and Embase were 
searched up to and including February 2010. Studies were 
also identified by checking the bibliographies of the articles 
retrieved. All RCTs with an adequate control group in which 
iron supply was provided by natural food sources, fortified 
foods, formula or supplements to infants, children or adoles-
cents until the age of 18 years were considered for inclusion. 
No language restrictions were applied. Fourteen studies met 
the selection criteria. Twelve out of these 14 studies had a 
high or moderate risk of bias. A large degree of heterogene-
ity of study populations, iron dosages and outcome mea-
sures precluded performing a quantitative meta-analysis. 
Overall, the studies suggest a modest positive effect of iron 
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could influence iron status include strenuous exercise, 
pregnancy, low socioeconomic status and ethnicity, as 
well as disease-induced malabsorption and chronic blood 
loss  [5] or polymenorrhea in girls  [6, 7] . Prevalence esti-
mates of iron deficiency (ID) in adolescent girls range 
from 9 to 40%, depending on the population studied and 
the criteria used to define ID  [8] . In children below 4 years 
of age, the estimated prevalence of ID ranges from 20% 
in industrialized countries to 39% in nonindustrialized 
countries  [9] . Anemia is considered to be a public health 
problem when the prevalence of low hemoglobin concen-
trations exceeds 5% in the population. The severity of the 
public health problem of anemia is classified according to 
the prevalence of anemia in the population as mild (5.0–
19.9%), moderate (20.0–39.9%) or severe ( 6 40%)  [10] . 
Worldwide, the estimated prevalence of IDA among pre-
school-aged children is 25%; among school children it is 
40%, and among adolescents it is 30–55%  [11] . The preva-
lence of ID and IDA in infants is difficult to assess. This 
is because rapid physiological changes in iron status oc-
cur during infancy, and there is no agreement on cut-off 
values of iron status indicators for ID and IDA.
 ID and IDA can have a serious impact on infants’ and 
children’s health and later development, i.e. alteration
of the immune status, adverse effects on morbidity, de-
layed behavioral and mental development, below average 
school achievements and growth retardation, as well as 
adverse effects on cognition that may or may not be re-
versible with iron treatment  [8, 12] . Although various 
studies have been performed using neurodevelopmental 
outcomes to assess iron requirements in infancy and 
childhood, results have been inconclusive. Different pop-
ulations have been studied at different ages with different 
developmental tests, which makes it difficult to compare 
the studies  [13] . Particular interest in preschool and 
school children has been shown. Most observational 
studies in children have found a significant association 
between IDA and poor cognitive and motor development 
 [14, 15] , showing that IDA is associated with lower scores 
on testing of intelligence quotients (IQs). Children 9–11 
years old with IDA obtained significantly lower scores on 
a standardized educational achievement test than did 
iron-replete children  [16] . However, it is not clear wheth-
er the ID causes the delay or merely whether the two find-
ings are associated evidence of an underprivileged envi-
ronment. It is also possible that an early neurodevelop-
mental insult caused by IDA may not result in detectable 
psychomotor delay during infancy, but symptoms such as 
deficits in attention and school performance appear later 
in older children, young adolescents and adults  [13] . In 
the longest follow-up study to date, in Costa Rica, chil-
dren identified at 12–23 months who had been treated for 
severe, chronic ID in infancy still showed differences as-
sociated with IDA at the age of 19 years as compared to 
peers who had good iron status during infancy  [15] .
 There is increasing evidence that low iron status ad-
versely influences physiological functions not only due to 
reduced hemoglobin synthesis but also because of de-
creased activity of iron-containing enzymes in the brain 
 [17] . Since in ID, iron appears to be preferentially chan-
nelled to hemoglobin synthesis, the brain may become 
iron depleted when intake is insufficient even if the indi-
vidual is not yet anemic  [17] . A number of animal studies 
show that ID changes the myelination of neurones, neu-
rometabolism, neurotransmitters and gene/protein pro-
files before and after iron repletion at weaning  [18] . Ro-
dent studies show effects of ID during gestation and lac-
tation that persist into adulthood despite restoration of 
iron status at weaning  [18] . A lack of sufficient iron intake 
may significantly delay the development of the central 
nervous system as a result of alterations in morphology, 
neurochemistry and bioenergetics  [19] .
 The role that iron plays in the neurodevelopment of 
anemic and nonanemic iron-deficient (NAID) infants, 
children and adolescents is not fully understood. An ef-
fect of iron treatment on cognition was not observed in 
most trials of children  ! 2 years of age with IDA, but it 
was observed in older children. In children  1 2 years of 
age and in adolescents with IDA, evidence suggests ben-
eficial effects of iron treatment on cognitive or behav-
ioral function; however, the insufficient number of stud-
ies, often associated with different confounders, prevents 
a thorough assessment.
 The European Micronutrient Recommendations 
Aligned (EURRECA) Network of Excellence attempts to 
consolidate the basis for the definition of micronutrient 
requirements across Europe, taking into account rela-
tionships among intake, status and health outcomes  [20] . 
Systematic reviews are being conducted on those micro-
nutrients that are deemed to be of major importance
for certain population groups, following a standardized 
methodology. This paper aims to review data from all 
available randomized controlled trials (RCTs) which met 
EURRECA’s quality standards, to ascertain the effect of 
iron intake on measures of cognitive development and 
function in infants, children and adolescents. Four sys-
tematic reviews on this topic have been published previ-
ously  [14, 21–23] . However, they were limited to specific 
age ranges (e.g. young children or infants  ! 1 year of age), 
considered only supplementation studies or focused on 
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either anemic or nonanemic subjects. Our review aimed 
to answer the following questions: (1) what is the effect of 
iron intake on cognitive development and function?, and 
(2) what factors affect this relationship? Any source of 
iron was considered (diet, formula, supplements and for-
tified foods), and studies were assessed independently of 
the iron status of subjects at baseline.
 Methods 
 This research is part of a project within the EURRECA net-
work that aims to identify micronutrient requirements for opti-
mal health in European populations (www.eurreca.org). The re-
view reported here was part of a wider review process to identify 
studies assessing the effect of iron intake on different outcomes 
(markers of iron status and health outcomes). No review protocol 
was registered.
 Search Methods for Identification of Studies 
 MEDLINE, Embase (both on Ovid) and the Cochrane Library 
CENTRAL database were searched up to and including February 
2010. The search strategy included terms for ‘[study designs in 
humans] AND [intake or status] AND [iron]’. Both indexing and 
text terms were used. The search strategy was adapted for each of 
the individual databases. The search was not limited by language. 
The search strategy for MEDLINE is presented in Appendix 1. 
The reference lists of retrieved articles and published reviews were 
also checked for relevant studies.
 Criteria for the Consideration of Studies for This Review 
 Studies had to fulfill the following criteria to be included in the 
review: (1) investigate how iron intake affect measures of cognitive 
development and function; (2) provide iron from supplements, 
fortified foods or natural dietary sources; (3) be RCTs with an ad-
equate control (placebo or no intervention); (4) study infants, chil-
dren or adolescents from birth to 18 years of age at the time of the 
intervention, and (5) include apparently healthy subjects.
 Some studies included interventions with more than one mi-
cronutrient. When the effect of iron was not measured separately, 
the studies were not considered for review. Studies had to report 
baseline data for the measured outcomes to be included in the re-
view. Studies on subjects with ID or IDA but otherwise healthy 
were included.
 Selection of Studies and Data Extraction 
 Firstly, titles and abstracts were screened to exclude any refer-
ences not meeting the inclusion criteria. Four independent re-
viewers were involved in data extraction. Two independent re-
viewers screened 10% of the references in duplicate. Any discrep-
ancies at the duplicate screening step were discussed before 
screening the rest of the references. The rest of the references 
(90%) were then divided among four reviewers who assessed if 
they were potentially relevant. The potentially relevant references 
were then located as full texts. All full texts were assessed twice 
for inclusion criteria by two independent reviewers. Disagree-
ments were settled through discussion. Only papers reporting 
studies meeting all inclusion criteria were included in the review. 
Data were then extracted into a standardized database, which in-
cluded bibliographic details, methodological details, population 
characteristics, study group details and outcome data. Data from 
30% of the total papers were extracted in duplicate. Any disagree-
ments were discussed to achieve a uniform approach to data ex-
traction. The remaining 70% of the papers was divided among 
four reviewers and extracted by a single reviewer.
 Assessment of Risk of Bias in Included Studies 
 In order to assess the quality of the study and the risk of bias, 
the following indicators of internal validity were collected during 
data extraction. These indicators are specific to the RCT meth-
odology: (1) method of sequence generation and allocation, (2) 
blinding, (3) potential funding bias, (4) number of participants at 
start, (5) dropouts and dropout reasons, (6) dose check (amount 
of iron provided), (7) dietary intake data reported, (8) outcome 
comparability and reproducibility, and (9) similarity at baseline 
of most and least exposed groups. Based on these indicators, two 
independent reviewers decided on the overall risk of bias. Dis-
agreements were resolved by discussion. The criteria for judging 
these indicators were adapted from the Cochrane Handbook  [24] . 
Additionally, we applied the Jadad score to assess the method-
ological quality of the studies  [25] . This procedure scores the stud-
ies according to the presence of the three key methodological fea-
tures of randomization, blinding and accountability of all pa-
tients, including withdrawals.
 Results 
 Fourteen studies were eligible and were included in the 
review.  Tables 1 and  2 show the key characteristics of the 
included studies on infants and young children, and on 
school-aged children and adolescents, respectively. Fig-
ure 1 shows the flow chart of the study selection process.
 Infants, Toddlers and Preschool Children 
 Seven studies on infants and preschool children were 
included. Five of them were conducted on infants and 
toddlers 6–24 months of age. A supplementation trial in 
24 nonanemic 6-month-old Turkish infants using doses 
of 1 mg/kg/day ferrous sulfate during 3 months showed 
no significant change in developmental test scores. The 
study used the Bayley Scales of Infant Development 
(BSID) Mental Development Index (MDI) scores and 
Psychomotor Development Index (PDI) scores  [26] .
 One study in Indonesia included anemic and nonane-
mic infants up to 12 months of age. The infants were treat-
ed with ferrous sulfate 10 mg/day alone, ferrous sulfate 
combined with zinc sulfate, zinc alone or placebo during 
6 months. This study, which included a sample size of 680 
subjects, indicated a small but significant positive effect of 
iron supplementation on motor development with single 
iron supplementation as assessed by the BSID (PDI score) 
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in all infants and in all groups. No significant effect was 
seen on cognitive development or behavior as assessed by 
the MDI score or Behavioral Rating Scale  [23] .
 A trial in Guatemala that provided short-term iron 
supplementation for 1 week to 68 anemic and nonanemic 
infants and children up to 24 months of age found no ben-
efit of the iron supplement when testing with the BSID. A 
dosage of ferrous ascorbate of 5 mg/kg was used  [27] .
 A study by Idjradinata and Pollitt  [12] in anemic and 
nonanemic 12- to 18-month-old children showed that 
iron treatment (3 mg/kg/day ferrous sulfate) during 4 
months significantly improved BSID results in iron-defi-
cient children. These even reached the performance level 
of iron-sufficient children, unlike the group treated with 
placebo (p  ! 0.001)  [12] .
 Two studies on anemic toddlers and young children in 
Europe (England and Greece) used outcomes other than 
BSID scales. Aukett et al.  [28] used 24 items from the 
Denver Developmental Screening Test validated by the 
BSID in children 17–19 months old. In this treatment tri-
al in a group of 110 anemic toddlers, 31% of them achieved 
6 or more new skills after treatment with iron (24 mg/day 
ferrous sulfate combined with vitamin C) during 2 
months, compared to 12% in the placebo plus vitamin C-
treated group (p  ! 0.05)  [28] . Simple reaction time, con-
tinuous performance task and oddity learning tasks were 
used by Metallinos-Katsaras et al.  [29] . Anemic children 
3–4 years old made significantly fewer errors of commis-
sion (14% higher specificity; p  ! 0.05) and exhibited 8% 
higher accuracy (p  ! 0.05) after 2 months of iron treat-
ment (15 mg of elemental iron daily, given as ferrous fu-
marate combined with multivitamins) than those given 
placebo (multivitamins without iron), suggesting im-
proved discrimination and selective attention, although 
no effects were found on the oddity learning task. These 
positive effects of iron were not seen among the children 
with good iron status  [29] .
 Soewondo et al.  [30] applied a discrimination learning 
task, oddity learning task and the Peabody Picture Vo-
cabulary Test in Indonesian children 4–5 years of age. 
They reported statistically significant positive changes 
for iron-depleted children treated with 50 mg/day iron 
during 2 months compared to the placebo group when 
applying the Peabody Picture Vocabulary Test. No sig-
nificant changes were seen for iron-depleted and anemic 
children, whereas changes in the iron-replete group were 
significant. When the oddity learning test was applied, 
the iron-replete children learned faster before treatment 
than did the anemic children (statistically significant for 
2 out of 4 tasks). Iron treatment did not have the same ef-
fect on the iron-replete and anemic children. After treat-
ment, the anemic children treated with iron obtained the 
best scores of all groups  [30] .
 School Children and Adolescents 
 The seven studies on school children and adolescents 
provided iron supplements in the form of ferrous sulfate 
 [8, 16, 31–35] . Four studies included children and adoles-
cents from 6 to 15 years of age  [29–32] , and 1 study in-
cluded 13- to 18-year-old adolescents  [8] . Two studies 
were performed on females only  [8, 33] .
 One study was conducted in the USA  [8] , whereas the 
others were conducted in Asia: 2 in India  [33, 34] , 2 in In-
donesia  [32, 35] and 2 in Thailand  [16, 31] . The dosages of 
supplemented iron varied widely. Doses between 2 and 60 
mg of elemental iron daily in the form of ferrous sulfate 
were used in 5 studies ( table 1 ). Bruner et al.  [8] used mark-
edly higher doses, i.e. 2  ! 2 tablets of 325 mg (1,300 mg in 
total) of ferrous sulfate daily in adolescent girls, which is 
equivalent to 260 mg of elemental iron daily. One of the 
studies conducted in Indonesia used a dose of iron that de-
pended on the weight of the children, i.e. 2 mg/kg/day  [32] , 
whereas the other Indonesian study provided iron doses of 
2 mg/day  [35] . Pollitt et al.  [16] increased the dose from 10 
mg/day in the first 2 weeks to 20 mg/day in the following 
14 weeks. The duration of the interventions ranged from 2 
to 4 months. In the 2 Indian studies, girls were treated for 
2  ! 60 days in a school year  [29, 30] . In most of the stud-
ies, children received the iron supplement daily during the 
intervention, except in the study by Sungthong et al.  [31] , 
in which children received 60 mg of elemental iron 5 times 
per week or the same dose once a week. One study  [33] was 
performed in anemic children, one study in NAID girls  [8] , 
one in apparently healthy children  [31] and 5 studies in 
both anemic and nonanemic children  [32, 34, 35] , 2 of 
them including an NAID group  [10, 14] .
 Two studies conducted in India used the same tests for 
assessment of cognitive function in children 8–15 years 
old, namely the Clerical Task test, Digit Span test, Mazes 
test and Visual Memory  [33, 34] . Bruner et al.  [8] used the 
Brief Test of Attention, Symbol Digit Modalities Test,
Visual Search and Attention Test and Hopkins Verbal 
Learning Test. Soemantri et al.  [35] measured education-
al achievement and tested concentration. In 3 studies, the 
authors measured IQ in children before and after iron 
intervention  [16, 31, 32] . The large diversity of tests em-
ployed in the different studies hampered any quantitative 
comparison of results or meta-analysis.
 In a study by Pollitt et al.  [16] , the IQ and scholastic 
achievement significantly increased in anemic children 
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and to a lesser degree in NAID children 9–11 years old, 
after 10 mg/day iron supplementation in the first 2 weeks 
and 20 mg/day in the following 14 weeks.
 Sungthong et al.  [31] reported a significantly greater 
increase in IQ in 6- to 13-year-old children treated with 
60 mg of iron once weekly for 16 weeks (6  8 12 points) 
or placebo (6  8 12 points) than in children treated with 
the same dose of 60 mg of iron 5 days a week (3  8 12), 
while no difference in learning achievement was found 
among the groups. 
 No statistically significant improvement in IQ was 
found in an Indonesian study in children who received
2 mg/kg/day iron for 3 months compared to the control 
group, but improved learning achievement scores were 
detected in anemic children treated with iron  [32] . An-
other Indonesian study by the same authors providing
2 mg/kg/day iron for 3 months detected significantly bet-
ter school achievement by nonanemic children compared 
to anemic children that persisted after treatment inde-
pendently of iron or placebo treatment  [35] .
 Sixty days of supplementation with 30 or 40 mg of
iron per day in 8- to 15-year-old anemic boys induced
a significant improvement in all cognitive functions
compared to the placebo group (p  ! 0.05), except for the 
Mazes test in the 30 mg/day group. No difference be-
tween the iron and placebo group was found in nonane-
mic boys  [34] . Girls of the same age were treated for 2  ! 
60 days with 60 mg/day iron. Significantly better scores 
on the Clerical Task test, Digit Span test and Mazes test 
were reported after 8 months in the anemic girls treated 
with iron versus placebo (p  ! 0.05), but not after 4 months 
 [33] . Similar results were found by Seshadri and Gopal-
das  [34] , but they also reported improved scores on the 
Mazes test in nonanemic girls after supplementation
with iron. Higher doses of 260 mg/day iron, given to 
NAID adolescent girls for 8 weeks, led to significantly bet-
ter results on a test of verbal learning and memory when 
compared to girls in the placebo group (p  ! 0.02)  [8] .
 Confounding Variables 
 Many factors are associated with both IDA and cogni-
tive function, including low socioeconomic status, pov-
erty, poor quality of stimulation in the home, low levels 
of maternal education, maternal depression, low birth 
weight, early weaning, parasitic infection and undernu-
trition  [36] . Some of these factors were present in most of 
the studies included in this review (e.g. low socioeconom-
ic status, poverty, parasitic infection and undernutrition).
 Risk of Bias and Quality of the Studies Included 
 Table  3 summarizes the internal validity of the in-
cluded studies, assessed as described in the Methods sec-
tion. The results show a high risk of bias in most of the 
studies. Only 2 studies  [12, 37] had a low risk of bias. Two 
studies had a moderate risk of bias  [8, 31] . The main rea-
sons for a high risk of bias were an unclear adequacy of 
sequence generation and/or allocation and inadequate 
information on funders. In most cases, insufficient in-
Table 3.  Assessment of validity (adapted from the Cochrane Handbook) and of quality (Jadad scale) of included RCTs on effects of 
iron supply on measures of cognitive development and function
Study Adequate
sequence
generation
Allocation
concealment
adequate
Blinding
adequate
Dropouts adequate 
and outcome
data complete
Information
on funder
adequate
Lack of other
potential threats
to validity
Overall
risk
of bias [24]
Jadad
score
[25]
Aukett  et al. 1986 [28] unclear yes yes yes unclear yes high 4
Bruner et al. 1996 [8] yes yes yes yes no yes moderate 5
Idjradinata and Pollitt 1993 [12] yes yes yes yes yes yes low 5
Kashyap and Gopaldas 1987 [33] unclear unclear unclear no yes yes high 2
Lind et al. 2004 [37] yes yes yes yes yes unclear low 5
Lozoff et al. 1982 [27] unclear unclear yes yes yes unclear high 4
Metallinos-Katsaras et al. 2004 [29] unclear yes yes yes no yes high 4
Pollitt et al. 1989 [16] unclear unclear yes unclear yes yes high 3
Seshadri and Gopaldas 1989 [34] unclear unclear unclear yes unclear yes high 2
Soemantri et al. 1985 [35] unclear unclear unclear unclear yes yes high 2
Soemantri et al. 1989 [32] unclear unclear yes yes yes yes high 4
Soewondo et al. 1989 [30] unclear unclear yes unclear yes yes high 3
Sungthong et al. 2004 [31] yes unclear yes yes yes yes moderate 4
Yalcin et al. 2000 [26] unclear unclear no yes unclear unclear high 3
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formation related to those criteria was given. When ap-
plying the Jadad score, 8 studies were classified as high-
quality studies (scores of 4 or 5) and 6 as low-quality 
studies (score  ^  3).
 Discussion 
 Evidence 
 This review of 14 RCTs has assessed the effects of iron 
supplementation on measures of cognitive development 
and function in infants, children and adolescents. The 
overwhelming feature of this review is the limited num-
ber of relevant studies that could be identified and in-
cluded in the review.
 Only one study provided iron supplements for less 
than 2 months  [27] . Based on this single study, there is no 
evidence of a positive effect of supplementation for 1 week 
on the mental and psychomotor development of anemic 
infants and children with and without IDA of 6–24 
months of age.
 For children aged 1–5 years, there is some evidence 
from 3 RCTs that iron supplementation during 2–4 
months may have a positive effect on the mental and psy-
chomotor development of anemic children  [12, 28, 29] .
 Eight RCTs in anemic and nonanemic children over 5 
years of age provided evidence for a positive effect of iron 
supplementation on different measures of cognition  [8, 
16, 30–35] . Due to the different parameters that were test-
ed in the studies, it was very difficult to compare the stud-
ies and to achieve firm conclusions.
 Given the data base available, it is not possible to derive 
clear evidence-based conclusions on the effect of iron 
supply on cognitive development and function in infants, 
children and adolescents. An important reason for this is 
that some of the trials originally had to be excluded be-
cause they did not have an adequate control group ac-
cording to our criteria. Furthermore, the presence of oth-
er confounding variables, such as other nutritional defi-
ciencies, low socioeconomic status and studies carried 
out in areas with endemic malaria, could have markedly 
influenced the results obtained.
 Another remarkable limitation is the considerable het-
erogeneity of the study populations, which makes it dif-
ficult to compare and combine the available results. The 
heterogeneity of outcome measures precluded pooling 
study results quantitatively in a meta-analysis. The as-
sessment of validity showed that most studies had a high 
risk of bias, independent of the methodological quality as 
assessed by the Jadad score.
Titles and abstracts identified from trials included
in reviews and bibliography lists and not retrieved 
by electronic search 
n = 43  
Excluded 
n = 5,011 
Papers excluded as only abstract available,
correction to an already included trial, no RCTs,
cluster-randomized controlled trials, not relevant
interventions, no adequate control group,
no amount of iron given reported, no values 
provided for outcomes of interest, no baseline
data for outcomes of interest reported, outcomes
other than cognitive development and function
n = 394
Titles and abstracts identified
from electronic search and
screened (limited to RCTs)
n = 5,376  
Full copies of publications on
trials in infants, children and
adolescents retrieved and 
assessed for eligibility 
n = 408  
Publications with outcome 
cognition meeting 
EURRECA inclusion criteria 
n = 14   Fig. 1. Flow diagram for the systematic re-
view. 
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 Comparison with Other Systematic Reviews 
 Unlike other systematic reviews on the topic, the pres-
ent systematic review was not limited to supplementation 
studies. However, only supplementation trials complied 
with our inclusion criteria. Because we selected studies 
independently of the baseline iron status of participants, 
our systematic review covers trials on NAID and anemic 
iron-deficient subjects. In addition, our review includes 
studies performed in subjects across all age ranges from 
0 to 18 years.
 Effect of Iron in Nonanemic Subjects 
 A recent review with meta-analysis by Szajewska et al. 
 [23] analyzed the effects of iron supplementation in non-
anemic infants and young children on the mental perfor-
mance and psychomotor development of children ( ! 3 
years). The 5 included RCTs did not individually show a 
beneficial effect of iron supplementation on the MDI of 
the BSID at different ages throughout the first 18 months. 
Three of the 5 RCTs showed a beneficial effect of iron 
supplementation on the PDI at some time points, where-
as the other 2 did not. The authors performed 2 meta-
analyses of 3 RCTs involving 561 infants and children.
It was concluded that iron supplementation in infants 
may positively influence children’s psychomotor develop-
ment, whereas it does not seem to alter their mental devel-
opment or behavior. Only 2 of the 5 RCTs on nonanemic 
infants included in this review were included in our re-
view  [26, 37] . The other 3 were found by our search, but 
they were excluded because of lack of baseline data for the 
outcomes reported or because the exact quantity of iron 
supplied was not reported.
 Effect of Iron in Anemic and Nonanemic Subjects 
 In 2005, Sachdev et al.  [14] published a systematic re-
view with a meta-analysis examining the effects of iron 
supplementation in relation to development in children. 
The review included 17 trials of oral iron supplementa-
tion, fortified milks and cereal and parenteral iron (all 
RCTs) involving 3,646 participants. The authors conclud-
ed that iron supplementation had modest but significant 
beneficial effects on mental development in children who 
were anemic or iron deficient at baseline and in all chil-
dren  1 7 years old, particularly with regard to IQ scores. 
In younger children (aged  ! 27 months), no effect of iron 
supplementation on mental development was detected. 
Motor development was not found to be improved 
through iron supplementation. Out of the 17 trials in-
cluded in the review of Sachdev et al.  [14] , 6 were also in-
cluded in our review. The rest were identified in the 
search but then excluded because the exact iron dose was 
not reported (1 study), the study was not randomized (2 
studies), there was no control group (1 study), there was 
no adequate control group (1 study) and values for out-
comes after supplementation were not reported (1 study).
 A review by Iannotti et al.  [38] on the benefits and risks 
of iron supplementation of infants and children under 5 
years of age in developing countries published in 2006 
concluded that providing additional iron via daily or 
weekly supplementation to preschool iron-deficient chil-
dren may have had some positive effects on developmental 
indicators, especially among children who were anemic or 
iron deficient at baseline. Eight studies were included in 
this review for the outcome ‘development’. Four of them 
were also included in our review. Those not included in 
our review did not report the amount of iron given to the 
study participants (1 study), the results were reported in 
such a way that we could not compare groups (1 study), the 
necessary values were not reported (1 study) or there was 
no control group for the outcome of interest (1 study).
 A Cochrane review by Martins et al.  [22] aimed to as-
sess the effects of iron supplementation of iron-deficient 
infants and children under 3 years of age, beginning sup-
plementation before 1 year of age, on measures of psycho-
motor development or cognitive function. Seven RCTs 
providing oral or intramuscular iron were included in 
this review, 5 of which assessed psychomotor develop-
ment between 5 and 11 days of commencement of thera-
py. It was concluded that there was no convincing evi-
dence that administration of iron improved scores on 
tests of psychomotor development within 6–11 days of 
treatment. The effect of longer interventions unfortu-
nately remained unclear from the results of the other 2 
studies, which assessed outcomes more than 30 days after 
commencing iron supplementation. Three studies in-
cluded in this review were also included in our review. 
From those not included in our review, 1 was an unpub-
lished study, 1 was excluded because the relevant values 
were not reported, 1 was cluster-randomized, 1 did not 
report the amount of iron supplied to study participants 
and another did not have an adequate control group for 
the outcomes of interest.
 Falkingham et al.  [21] recently published a systematic 
review assessing the effects of iron supplementation on 
cognition in older children ( 1 6 years) and adults. They 
included 14 RCTs and concluded that iron supplementa-
tion improved attention and concentration in all studies 
irrespective of baseline iron status. In anemic groups of 
children, supplementation improved IQ but had no effect 
on nonanemic participants. No effect of iron supplemen-
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tation on memory, psychomotor skills or scholastic 
achievement was found. However, the authors empha-
sized the limited number of studies included, which were 
generally conducted in small samples of subjects, had a 
short duration and were methodologically weak. Ten of 
the studies included in the review of Falkingham et al. 
 [21] were performed in children 6–18 years old. Five of 
them were not included in our review because of the fol-
lowing reasons: (1) 3 of the studies had no adequate con-
trol group according to our criteria, (2) 1 study had a lead-
exposed population (3) and in 1 study no baseline data 
were reported.
 Limitations of This Review 
 Four out of 7 studies on cognitive function in school 
children and adolescents included in this review had a 
supplementation period shorter than 12 weeks ( tables 1 , 
 2 ), which is considered hardly sufficient to alter the iron 
status [21]. This could have possibly negated the effects of 
iron supplementation. However, these studies showed 
similar effects on cognition compared to studies with 
longer supplementation periods. Additionally, a 3-month-
long study  [32] showed no effects of supplementation on 
IQ in anemic (and nonanemic) children, which the au-
thors explained by several factors such as mucosal block 
or other unidentified causes that were not detected dur-
ing the study (e.g. genetic factors that control absorption). 
Although a much longer duration of intervention is prob-
ably needed for outcomes such as scholastic achievement, 
where iron status during learning may be different from 
iron status at assessment of performance  [21] , they found 
improved learning results after iron supplementation.
 An important limitation of this review is the high risk 
of bias of most of the included papers. In most papers, the 
sequence generation and/or allocation were not well ad-
dressed according to our criteria or they were not clearly 
reported. Funders were judged inadequate or informa-
tion on funders was not reported in 4 studies on cogni-
tion ( table 3 ). Only 2 studies were assessed as having a low 
risk of bias.
 Development is often evaluated in a similar way in in-
fants and young children (e.g. BSID). In older children, 
different tests were used to assess developmental out-
comes. Thus, comparison between studies was more dif-
ficult. In addition, different iron status at baseline (ane-
mic, nonanemic and NAID subjects) and varying socio-
economic status of the participants make the assessment 
of the effects of iron interventions on cognitive functions 
difficult. The effects of iron might be rather different de-
pending on the baseline iron status.
 The reviewers tried to identify ongoing studies that 
could potentially be considered for inclusion in the re-
view. This was done by contacting experts in the field. 
No other means were applied to find unpublished re-
search, and so only published studies were included in 
the review. Thus, the review could be subject to publica-
tion bias because some unpublished studies may have 
been missed. 
 Recommendations for Practice and Research 
 Until more convincing evidence exists that iron sup-
plementation can significantly improve measures of 
cognitive function and development in infants, children 
and adolescents, policy should focus on prevention of 
IDA.
 RCTs in infants, children and adolescents should be 
conducted in a way that facilitates comparison with other 
studies and meta-analysis. Reporting studies in a stan-
dardized way would also contribute to a more evidence-
based nutrition. The Consolidated Standards of Report-
ing Trials statement  [39] should improve the reporting of 
RCTs.
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Appendix
Search strategy: MEDLINE February 2009 and February 2010 
Search 
No.
Search Results Search 
type
1 randomized controlled trial. pt. 261,515 advanced
2 controlled clinical trial. pt. 77,893 advanced
3 randomized. ab. 172,980 advanced
4 clinical trials as topic.sh. 140,006 advanced
5 randomly. ab. 125,849 advanced
6 randomized. ab. 33,552 advanced
7 (animals not (human and animals)). sh. 4,293,014 advanced
8 ((iron or ferric or ferrous or ferr*) adj3 (intake* or diet* or supplement* or deplet* or status or 
expos* or concentration*)). ti, ab.
14,306 advanced
9 (hemoglobin* or haemoglobin*). ti, ab. 84,956 advanced
10 ((serum adj3 ferritin) or (plasma adj3 ferritin) or (serum adj3 apoferritin) or
(plasma adj3 apoferritin) or (serum adj3 ‘transferrin receptor*’) or
(plasma adj3 ‘transferrin receptor*’) or (serum adj3 TFR*) or (plasma adj3 TFR*)). ti, ab.
6,042 advanced
11 *iron, dietary/ 806 advanced
12 (iron or ferrous or ferric or ferr*). ti, ab. 116,185 advanced
13 (intake* or diet* or fortif* or supplement* or deplet* or status or concentration* or expos*).ti,ab. 2,148,582 advanced
14 nutritional support/ or dietary supplements/ or nutritional requirements/ or
exp nutritional status/ or exp deficiency diseases/ or supplementation/
108,850 advanced
15 diet supplementation/ or dietary intake/ or exp diet restriction/ or exp mineral intake/ or diet/ or
food, fortified/ or nutrition assessment/ or nutritive value/
94,854 advanced
16 6 or 4 or 1 or 3 or 2 or 5 578,036 advanced
17 16 not 7 516,057 advanced
18 10 or 9 89,036 advanced
19 13 or 15 or 14 2,231,529 advanced
20 11 or 12 116,199 advanced
21 18 or 19 2,289,421 advanced
22 21 and 20 46,409 advanced
23 22 or 8 46,409 advanced
24 23 and 17 2,311 advanced
25 breast feeding/ or exp infant food/ 26,392 advanced
26 bottle feeding/ 2,725 advanced
27 25 or 26 27,172 advanced
28 infant formula/ 1,023 advanced
29 27 or 28 27,172 advanced
30 19 or 29 2,248,563 advanced
31 18 or 30 2,306,432 advanced
32 8 or 31 2,306,432 advanced
33 32 and 20 46,494 advanced
34 33 and 17 2,321 advanced
pt = Publication type; ab = abstract; sh = subject heading; adj3 = adjacency (terms in any order with three words (or fewer) between 
them); ti = title.
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